Sarepta amends CEO Ingram's stock option; 33% vests immediately; new targets to 2025

Sarepta Therapeutics, Inc.

33.33% (1,099,890 shares) of performance option vested effective April 19, 2022; remainder eligible through June 26, 2025.
Unvested portion triggers at stock prices $105.74, $128.65, $155.37, $186.36, requiring relative CAGR vs Biotech Index.
New one-year holding period on shares acquired upon exercise, except for change in control, death, disability, or certain terminations.
Change-in-control vesting requires minimum $130/share sale price if within 18 months; else next column applies.
Company expects significant non-cash accounting charge for the amendment; to be disclosed in upcoming 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.